In addition to new generation osimertinib [2], three EGFR-tyrosine kinase inhibitors (TKIs)–afatinib, erlotinib, and gefitinib—are commonly used as first-line therapies for advanced NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.